Results 11 to 20 of about 22,252 (260)
Insight into advances for the biosynthetic progress of fermented echinocandins of antifungals
Microbial Biotechnology, 2023 Invasive fungal infections have increased remarkably, which have become unprecedented concern to human health. However, the effectiveness of current antifungal drugs is limited due to drug resistance and toxic side‐effects.
Kaili Jiang +3 more
doaj +2 more sources
Review on Current Status of Echinocandins Use
Antibiotics, 2020 Fungal infections are rising all over the world every year. There are only five medical compound classes for treatment: triazoles, echinocandins, polyenes, flucytosine and allylamine.
Martyna Mroczyńska +1 more
doaj +2 more sources
Journal of Fungi, 2020 Rezafungin (formerly CD101) is a new β-glucan synthase inhibitor that is chemically related with anidulafungin. It is considered the first molecule of the new generation of long-acting echinocandins. It has several advantages over the already approved by
Guillermo Garcia-Effron
doaj +2 more sources
In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris
Antibiotics, 2021 Candida auris is an emergent fungal pathogen that causes severe infectious outbreaks globally. The public health concern when dealing with this pathogen is mainly due to reduced susceptibility to current antifungal drugs.
Guillermo Quindós Andrés +2 more
exaly +2 more sources
Nature CommunicationsAntifungal echinocandins inhibit the biosynthesis of β−1,3-glucan, a major and essential polysaccharide component of the fungal cell wall. However, the efficacy of echinocandins against the pathogen Aspergillus fumigatus is limited.
Malitha C. Dickwella Widanage +10 more
doaj +2 more sources
Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence [PDF]
Journal of Fungi, 2016 Aspergillus spp. are a group of filamentous molds that were first described due to a perceived similarity to an aspergillum, or liturgical device used to sprinkle holy water, when viewed under a microscope.
Ethan R. Stewart, George R. Thompson
doaj +10 more sources
Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance
International Journal of Infectious Diseases, 2020 INTRODUCTION A possible increase of Candida resistance, specially in C. glabrata, has been speculated according to a poor diffusion of echinocandins to peritoneal fluid.
Francesca Gioia +2 more
exaly +2 more sources
Colistin interacts synergistically with echinocandins against Candida auris
International Journal of Antimicrobial Agents, 2020 Antifungal combination is an interesting approach for the treatment of several fungal infections but there is currently little evidence to support combined therapy in C. auris infections.
Eric Dannaoui
exaly +2 more sources
Echinocandins as Biotechnological Tools for Treating Candida auris Infections
Journal of Fungi (Basel, Switzerland), 2020 Candida auris has been reported in the past few years as an invasive fungal pathogen of high interest. Its recent emergence in healthcare-associated infections triggered the efforts of researchers worldwide, seeking additional alternatives to the use of ...
Elizabete de Souza Cândido +2 more
exaly +2 more sources
Susceptibility of Candida glabrata biofilms to echinocandins: alterations in the matrix composition [PDF]
Biofouling (Print), 2018 Candidiases are the most recurrent fungal infections, especially among immunosuppressed patients. Although Candida albicans is still the most widespread isolated species, non-Candida albicans Candida species have been increasing.
Arendrup MC +9 more
core +2 more sources